| Balance Sheets | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 2,203 | 2,161 | 1,697 | 3,319 |
| Accounts receivables, net of allowance for credit losses of 82million and 78million as of september30, 2025 and december31, 2024, respectively | 3,810 | 3,564 | 3,384 | 3,462 |
| Inventories | 3,323 | 3,497 | 3,247 | 3,959 |
| Prepaid expenses | 1,115 | 1,084 | 1,018 | 1,127 |
| Other current assets | 477 | 472 | 368 | 445 |
| Assets held for sale | 1,809 | 1,842 | 1,814 | 2 |
| Total current assets | 12,736 | 12,620 | 11,528 | 12,314 |
| Deferred income taxes | 1,634 | 1,781 | 1,762 | 2,070 |
| Othernon-currentassets | 444 | 470 | 464 | 459 |
| Property, plant and equipment, net | 4,820 | 4,810 | 4,631 | 5,672 |
| Operating lease right-of-use assets, net | 342 | 358 | 363 | 364 |
| Accumulated amortization-In Process Research And Development | 0 | 0 | 0 | 0 |
| Gross carrying amount net of impairment | 17,139 | 17,207 | 16,764 | 17,287 |
| Accumulated amortization | 13,203 | 13,065 | 12,575 | 12,531 |
| Identifiable intangible assets, net | 3,936 | 4,142 | 4,189 | 4,756 |
| Goodwill | 15,945 | 15,949 | 15,477 | 16,124 |
| Total assets | 39,856 | 40,131 | 38,415 | 41,758 |
| Short-term debt | 24 | 464 | 421 | 2,580 |
| Sales reserves and allowances | 4,134 | 4,050 | 3,696 | 3,785 |
| Accounts payables | 2,355 | 2,498 | 2,290 | 2,371 |
| Employee-related obligations | 561 | 481 | 474 | 619 |
| Accrued expenses | 2,989 | 3,095 | 2,952 | 2,984 |
| Other current liabilities | 1,103 | 940 | 964 | 1,241 |
| Liabilities held for sale | 324 | 334 | 358 | 216 |
| Total current liabilities | 11,491 | 11,861 | 11,157 | 13,797 |
| Deferred income taxes | 399 | 440 | 461 | 538 |
| Other taxes and long-term liabilities | 3,664 | 3,938 | 4,011 | 4,344 |
| Senior notes and loans | 16,766 | 16,763 | 16,230 | 16,400 |
| Operating lease liabilities | 283 | 296 | 288 | 295 |
| Total long-term liabilities | 21,111 | 21,436 | 20,990 | 21,578 |
| Total liabilities | 32,602 | 33,297 | 32,146 | 35,375 |
| Redeemable non-controlling interests | 0 | 0 | 0 | - |
| Ordinary shares of nis 0.10 par value per share september30, 2025 and december31, 2024 authorized 2,495million shares issued 1,253million shares and 1,240million shares, respectively | 58 | 58 | 58 | 58 |
| Additionalpaid-incapital | 28,038 | 28,003 | 27,965 | 27,860 |
| Accumulated deficit | -14,243 | -14,676 | -14,958 | -14,956 |
| Accumulated other comprehensive loss | -2,475 | -2,431 | -2,675 | -2,769 |
| Treasury shares as of september30, 2025 and december31, 2024 106million and 107million ordinary shares, respectively | 4,128 | 4,128 | 4,128 | 4,128 |
| Stockholders' equity attributable to teva shareholders | 7,250 | 6,827 | 6,262 | 6,065 |
| Non-controlling interests | 4 | 7 | 7 | 319 |
| Total equity | 7,254 | 6,834 | 6,269 | 6,383 |
| Total liabilities, redeemable non-controlling interests and equity | 39,856 | 40,131 | 38,415 | 41,758 |
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)